Evofem Biosciences, Inc.
Evofem Biosciences, Inc. (EVFM) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
evfm · stock forecast · 9 analysts (3M) · FMP · updated May 20, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$66.25
Consensus
$66.25
+883233.3% upside
Low
$66.25
Median: $66.25 · Last Close: $0.01
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.01 | ↑ 5.00% |
1-day model range: $0.01–$0.01. Peak: $0.01 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · EVFM · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-10-13 | Stifel | Downgrade ↓ | Buy→Hold |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-07-15 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-06-02 | Laidlaw & Co. | Maintains | Buy→Buy |
| 2022-05-25 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-05-11 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-05-10 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-04-12 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-03-04 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2021-11-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Evofem Biosciences, Inc. (EVFM) stock. Of the recent 25 rating actions, 0 were upgrades and 2 were downgrades. 9 analysts currently cover EVFM.
Analyst Recommendation Trends
EVFM analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$33M
↓ 73.4% YoY
Revenue Next Year
$19M
↓ 44.1% YoY
EPS This Year
$-995.00
EPS Next Year
$-7.80
↓ 99.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast EVFM EPS of $-995.00 for the current fiscal year, based on estimates from 1 analysts. The EVFM revenue forecast is $33M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The EVFM stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus EVFM price target is $66.25 (+883233.3% upside), with an analyst consensus of Buy.
The EVFM short-term stock prediction for tomorrow is $0.01 (+5.00%).
Evofem Biosciences, Inc. trades on OTC under the ticker EVFM. The EVFM stock outlook for 2027 is broadly positive, supported by a Buy consensus among 78% of covering analysts.
Frequently asked questions
EVFM forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month EVFM price target is $66.25, with a high forecast of $66.25 and a low of $66.25. The median price target is shown in the chart above when available. This implies +883233.3% potential upside from the current price of $0.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.